Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States



Survival: 28.9 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Memorial Sloan-Kettering Cancer Center
   
Journal: Link
   
Date: 1/2014

Description:
Patients:
This phase 3 study involved female HER2-positive metastatic breast cancer patients who were divided into two separate treatment groups. Group A consisted of 181 patients and group B had 182 patients. No patient age information was available.

Treatment:
Patients in group A received chemotherapy with nonpegylated liposomal doxorubicin and paclitaxel in addition to biologic therapy with trastuzumab.

Patients in group B received chemotherapy with paclitaxel and biologic therapy with trastuzumab.

Toxicities:
Treatment-related deaths due to unspecified causes were reported for group A. Grade 3-4 neutropenia, leucopenia, and stomatitis (inflammation of the lining of the GI tract) were also reported.

Treatment-related deaths due to unspecified causes were reported for group B. Grade 3-4 neutropenia and nerve toxicity were also reported.

Results:
The median overall survival times for groups A and B were 33.6 and 28.9 months, respectively.

Support:
This study was supported by Sopherion Therapeutics, makers of nonpegylated liposomal doxorubicin (brand name: Myocet).

Correspondence: Dr. Josť Baselga; email: baselgaj@mskcc.org

E-mail to a Friend Email Physician More Information